Net Sales are expected to increase by 3.5 percent Q-o-Q (up 21.5 percent Y-o-Y) to Rs 1017 crore, according to Centrum.

Will scale up contract mfg; $200 mn capex for key arms: Syngene

Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.

Strong biologics performance boosted Q1: Biocon CMD Kiran Shaw

The most important news that everyone will be tracking is when we submit dossiers in Europe and US for insulin Glargine and that as we have indicated will happen this fiscal, says Kiran Mazumdar Shaw

Biocon Q1 net seen down 5%, contract research may drive revenue

Factors to watch out for in Q1 would be margin, contract research business, R&D cost, pricing pressure in legacy API biz (especially statins), recovery in branded formulation (was flat in Q4 due to restructuring) and pick up in Middle East market (did well in Q4).

Biosimilar insulin Glargine to make $100 m from FY18: Biocon

Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.

Biocon Q4 profit seen at Rs 108 cr, Syngene may drive growth

Analysts feel growth ex-Syngene (ex-contract research: CRO) is likely to be subdued at around 4-7 percent, similar to Q3.

Biocon Q3 profit seen up 16%, biopharma may impact revenue

Profit growth may be led by higher revenue and margin improvement but revenue growth may get impacted by biopharma segment. Slow recovery in Middle East market and Fidaxomicin supplies may pressure Biopharma.

Hedging protects co from currency volatility: Syngene's COO

Manoj Nerurkar, COO, Syngene, says he expects the company to grow in line with its second quarter results.

Will focus on capacity expansion, customer needs: Syngene

Peter Bains, Director & CEO of Syngene told CNBC-TV18 growing client base and expanding capacity will aid growth in future.

Biocon Q2 profit seen up 5.8%, CRO may drive revenue growth

Analysts feel revenue growth during the quarter may be led by clinical research organisation (CRO) division while capacity constraints in insulins, lower offtake in Fidaxomicin and adverse business environment in Middle East markets may impact Q2 earnings.

Biocon Q1 net seen up 1.2% at Rs 104.3 cr: Motilal Oswal

Sales are expected to increase by 0.6 percent Q-o-Q (up 16.2 percent Y-o-Y) to Rs 835.3 crore, according to Motilal Oswal.

Biocon Q1 profit seen up 1%, revenue may jump 14%: Poll

Revenue is seen rising 14.3 percent year-on-year to Rs 829 crore in the quarter ended June, supported largely by lower base in the year-ago period (Revenue of Rs 725 crore, up 3.5 percent over Q1FY14).

Rationalising products to become specialised player: Biocon

Biocon's Kiran Mazumdar Shaw said the company deliberately took a hit on its topline in order to rationalize products. Biocon is focusing towards being a specialized products player.

Biocon Q4 profit seen down 8.5% to Rs 103.35 cr: Poll

Biocon's fourth quarter (January-March) profit is seen falling 8.5 percent year-on-year to Rs 103.35 crore due to weak operational numbers, according to the average of estimates of analysts polled by CNBC-TV18.

Biocon Q3 profit seen up 2.4% at Rs 107.5 cr: Poll

Biocon's third quarter profit is likely to increase 2.4 percent year-on-year to Rs 107.5 crore, according to the average of estimates of analysts polled by CNBC-TV18. The profit may be supported by other income.

Like Symphony, KPIT Tech; shun Kewal Kiran: Edelweiss

Vinay Khattar, Associate Director & Head of Research, Edelweiss Financial Services said that Q2FY15 earnings performance of Keval Kiran Clothing was a miss given the company‘s high cost increases.

Biocon Q2 profit may rise 9% to Rs 111.3 cr: CNBC-TV18 Poll

Pharmaceutical firm Biocon, which will declare its second quarter earnings today, is expected to report a 9 percent rise in profit at Rs 111.3 crore compared to Rs 102.15 crore in the year-ago period.

Biocon says confident of maintaining margins in Q4

Third quarter sales for Biocon were lower than street's expectations (Rs 700 crore vs Rs 759 crore) but EBITDA was higher. This was due to margin expansion that resulted from temporary low R&D spend, said Kiran Mazumdar-Shaw. The company would maintain margins in the fourth quarter by changing product mix and focusing on high-margin products.

Biocon Q3 PAT may rise by 14% at Rs 104.6cr: Dolat Capital

Sales of Biocon are expected to rise by 5.9 percent Q-o-Q (up 22.6 percent Y-o-Y) to Rs 777.6 crore.

Biocon Q3 PAT seen up 17% at Rs 107 cr: ICICIdirect

Revenues of Biocon are expected to rise by 3.3 percent Q-o-Q (up 19.1 percent Y-o-Y) to Rs 765.5 crore, according to ICICIdirect.com.

Biocon Q3 PAT seen up 19%, revenue may grow 20%: Poll

Core sales growth of 20 percent will be led by biopharma, India formulations and CRAMS business, analysts say, adding Biopharma will be lead by immunosuppressants (Serolimus) and insulin in emerging markets.

To list clinical research arm after it steadies: Biocon

The biotech major Wednesday reported a better-than-expected 17 percent year-on-year increase in sales for the September quarter, helped by a 46 percent surge in revenues from its clinical research business.

Biocon Q2 PAT may grow 3.2%, margin may stay over 20%: Poll

Profit after tax will increase with a slower pace (percentage wise) due to higher other income in a year ago quarter. It had received one off income of Rs 31 crore on account of compensation received from a few partners in second quarter FY13.

Biocon Q2 PAT seen up 7.3% at Rs 96.2 cr: ICICIdirect

According to ICICIdirect.com, Biocon may report a 2.9 percent growth quarter-on-quarter (up 7.3 percent Y-o-Y) in net profit at Rs 96.2 crore.

Biocon Q2 PAT seen up 7.1% at Rs 95.9 cr: Motilal Oswal

According to Motilal Oswal, Biocon to report a 2.6 percent growth quarter-on-quarter (up 7.1 percent Y-o-Y) in net profit at Rs 95.9 crore.